Siltuximab (INN), sold under the brand name Sylvant, is used for the treatment of people with multicentric Castleman's disease. It is a chimeric (made...
12 KB (924 words) - 14:49, 14 June 2024
treatment for iMCD is anti-IL-6 therapy with siltuximab (or tocilizumab, if siltuximab is not available). Siltuximab is the only FDA-approved treatment for...
23 KB (2,400 words) - 11:30, 31 August 2024
directed against the IL6-receptor. The second, siltuximab (Sylvant), is directed against IL-6 itself. Siltuximab is approved for treatment of human immunodeficiency...
12 KB (1,289 words) - 19:20, 4 December 2023
features of iMCD, and blockade of the IL-6 pathway using the medications siltuximab and tocilizumab effectively treats some patients with iMCD. However, many...
27 KB (3,189 words) - 15:37, 14 June 2024
Ravulizumab Risankizumab Ritlecitinib Rozanolixizumab Sarilumab Satralizumab Siltuximab Siponimod Sirukumab Spesolimab Sutimlimab Tildrakizumab Tofacitinib Upadacitinib...
7 KB (299 words) - 13:45, 27 April 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
22 KB (1,812 words) - 09:08, 9 October 2024
antibody preparation directed against B cells bearing the CD20 antigen, or siltuximab, a monoclonal antibody preparation directed against interleukin-6, may...
24 KB (2,233 words) - 16:16, 21 September 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
37 KB (2,868 words) - 23:35, 14 October 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
14 KB (1,037 words) - 22:20, 19 September 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
17 KB (1,245 words) - 14:04, 2 September 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
24 KB (2,084 words) - 23:47, 14 October 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
22 KB (2,581 words) - 20:03, 21 June 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
49 KB (6,005 words) - 13:33, 14 October 2024
Tocilizumab L04AC08 Canakinumab L04AC09 Briakinumab L04AC10 Secukinumab L04AC11 Siltuximab L04AC12 Brodalumab L04AC13 Ixekizumab L04AC14 Sarilumab L04AC15 Sirukumab...
3 KB (367 words) - 15:37, 25 January 2024
silperisone (INN) Silphen siltenzepine (INN) silteplase (INN) Siltussin-CF siltuximab (USAN, INN) Silvadene simaldrate (INN) simenepag (USAN, INN) simendan...
4 KB (264 words) - 05:09, 18 July 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
63 KB (7,473 words) - 11:32, 1 September 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
18 KB (1,654 words) - 05:40, 1 July 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
14 KB (1,578 words) - 23:52, 11 October 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
43 KB (3,675 words) - 23:48, 14 October 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
5 KB (286 words) - 05:02, 7 September 2024
IFN-α systemic lupus erythematosus (SLE), dermatomyositis, polymyositis Siltuximab Sylvant mab chimeric IL-6 Y cancer Simtuzumab mab humanized LOXL2 fibrosis...
136 KB (4,079 words) - 00:12, 12 October 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
14 KB (1,147 words) - 07:33, 11 August 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
16 KB (1,451 words) - 18:24, 2 August 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
12 KB (880 words) - 17:44, 5 October 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
45 KB (4,194 words) - 12:36, 2 May 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
43 KB (5,000 words) - 12:13, 15 September 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
26 KB (3,273 words) - 08:48, 14 October 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
22 KB (2,510 words) - 04:11, 12 August 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
40 KB (4,619 words) - 05:18, 22 August 2024
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See...
15 KB (1,264 words) - 06:00, 18 July 2024